Alnylam promotes Dr. Akshay Vaishnaw to President; continues scientific leadership

ALNYLAM PHARMACEUTICALS, INC.

Dr. Vaishnaw appointed President effective Jan 1, 2022; previously President of R&D.
Receives $725,000 base salary, 60% target bonus, and $2M stock option grant vesting over 4 years.
Yvonne Greenstreet named CEO effective same date; Vaishnaw to lead sustainable innovation in R&D.
Vaishnaw has been at Alnylam since 2006; also serves on boards of Editas Medicine and Scholar Rock.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Akshay K. Vaishnaw

President

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2022-01-01
Filed: January 4, 2022, 6:59 PM ET

On January 4, 2022, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Akshay K. Vaishnaw, M.D., Ph.D., the Company’s current President, Research and Development, as President effective January 1, 2022.

Role change

Yvonne L. Greenstreet

Chief Executive Officer

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2022-01-01
Filed: January 4, 2022, 6:59 PM ET

As previously announced, Yvonne L. Greenstreet, MBChB, MBA, the Company’s former President and Chief Operating Officer, was appointed Chief Executive Officer effective January 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Akshay K. Vaishnaw was appointed as President at ALNYLAM PHARMACEUTICALS, INC..

Action: appointed
Role: President

Exact text from the filing

On January 4, 2022, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Akshay K. Vaishnaw, M.D., Ph.D., the Company’s current President, Research and Development, as President effective January 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

As previously announced, Yvonne L. Greenstreet, MBChB, MBA, the Company’s former President and Chief Operating Officer, was appointed Chief Executive Officer effective January 1, 2022.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-001706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.